-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
An international team of dozens of scientists has reported two powerful melioth antibodies and revealed how they identify and stop virally infected cells.
preclinical studies have shown that the use of both antibodies alone or in a mixture can protect animals from new coronavirus infections.
that because different antibodies use different mechanisms of work, the combination of "cocktail" therapy will help combat the mutation of the new coronavirus resistance.
the study, scientists isolated B cells from two recovering patients with severe COVID-19 and screened nearly 800 monoclonal antibodies targeting the new coronavirus pyrethroid protein.
two powerful meso-antibodies, S2E12 and S2M11, stood out, with the semi-inhibitory concentrations (IC50) of the mesostrovirus as low as 0.04 nM and 0.02 nM, respectively.
antibody S2E12 and S2M11 targeting the new coronavirus pyrethroid proteins (Photo Source: Reference 1) Animal anti-venom experiments have shown that these two antibodies can have good protective effects at very low doses.
of the various human-source monoantibodies tested with hamster models, this is the lowest dose of antibodies currently required.
" paper points out.
researchers injected hamsters with S2E12, S2M11 and two mono-resistant mixtures, respectively, and exposed them to the new coronavirus after 48 hours.
4 days later, when they examined the animal's lung tissue and found that, using either a monoantigen alone or a combination of two antibodies, prophylactic injection effectively eliminated the replication of the virus in the lungs, reducing the number of viral nucleic acids by two to five orders of magnitude compared to the control group.
results show that S2E12 and S2M11 and their composition of the "cocktail" can provide strong protection against the replication of the new coronavirus in animals (Photo Source: Reference 1) For the two powerful antibodies, the researchers also made a detailed analysis, using cryo-EM to determine their role at the molecular level.
3D structural data show that both S2E12 and S2M11 can identify the bind binding domain (RBD) of the new coronavirus hedgehog protein, competitively preventing the host cell ACE2 binder from being combined with RBD.
In addition to directly blocking the interaction between the virus and the receptor, S2M11 can also lock the hedgehog protein into an inactive configuration that cannot bind the receptor, which means that the virus will not be able to fuse with the cell membrane, resulting in the inability to invade the cell.
S2M11, in combination with the hedgehog protein trimer, locks the virus into a state that cannot bind to the subject (Photo: Reuters) The study was led by the University of Washington and Biotechnology, inc. , which specializes in the development of infectious disease therapies.
Not so long ago, the research team developed a medium-range antibody S309 that demonstrated "broad-spectrum" anti-coronavirus potential in in-body trials, and the optimized version based on S309 is currently being evaluated in clinical Phase 2/3 trials.
the researchers note in their paper that combinations of S2M11 and S2E12, or their mixtures with S309, can have synergies with the efficacy of the medium.
Because of its unique and complementary mechanism of effect, the different formulations of antibody "cocktails" will help neutralization of many different viral mutants, thereby controlling the spread of the virus and reducing the problems caused by drug-resistant mutations for clinical applications.
to determine safety and verse, the study's two new powerfully validated antibodies and their combinations also need to be subsequently validated through human trials.
expect more good news from the results of clinical trials! Ref. M. Alejandra Tortorici et al., (2020) Ultrapotent human humanbodies antibodies antibodies protect against SARS-CoV-2 challenge via multiple mechanisms. Science. DOI: 10.1126/science.abe3354 [2] Ultrapotent antibody mix blocks COVID-19 virus attachment. Retrieved Nov. 23, 2020, from。